Selgantolimod - Gilead Sciences
Alternative Names: GS 9688; SLGN - Gilead SciencesLatest Information Update: 28 Jun 2025
At a glance
- Originator Gilead Sciences
- Developer Gilead Sciences; INSERM
- Class Antivirals; Hepatoprotectants; Small molecules
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Hepatitis-B in Australia (PO, Tablet)
- 15 Nov 2024 Efficacy and adverse event data from phase Ib trial in Hepatitis B presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024 )
- 15 Nov 2024 Interim efficacy data from a phase II trial in Hepatitis B presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)